The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Comparing four different methods of treatment, an analytic model showed that an all-oral, interferon-free, treat-all regimen was the most cost-effective approach for treating chronic Hepatitis C genotype 1.
Continue reading »In a Phase III Hepatitis C trial of triple therapy with pegylated interferon and ribavirin, simeprevir proves itself by leading to sustained virologic response in nearly 80 percent of patients.
Continue reading »
"Although the physiological mechanics between thyroid disorders and Hepatitis C remain elusive, an association between the two is irrefutable."
Continue reading »Thanks to a study indicating a much higher prevalence of this infectious virus than formerly reported, advocates of routine Hepatitis C screening gain more support.
Continue reading »Deciding whether or not to tell your boss you have Hepatitis C is a multifaceted issue that requires education, planning and support.
Continue reading »Due to positive results from three Phase III trials, the FDA has granted a priority review to simeprevir, a Hepatitis C protease inhibitor that is administered with interferon and ribavirin therapy.
Continue reading »Major improvements in Hepatitis C treatment response were seen when simeprevir was added to interferon-based therapy.
Continue reading »Although significant selenium supplementation must be done under a doctor’s supervision, this trace mineral could boost Hepatitis C therapy’s effectiveness.
Continue reading »In a small, open-label Phase II Hepatitis C study, an interferon-free and ribavirin-free combination of three direct-acting antivirals led to treatment success rates in the 90th percentile.
Continue reading »
With potential applications ranging from improving medical research to creating a liver suitable for transplant, Organovo has successfully created human liver tissue with 3D-bioprinting.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
